[go: up one dir, main page]

AU2003288231A1 - Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease - Google Patents

Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease

Info

Publication number
AU2003288231A1
AU2003288231A1 AU2003288231A AU2003288231A AU2003288231A1 AU 2003288231 A1 AU2003288231 A1 AU 2003288231A1 AU 2003288231 A AU2003288231 A AU 2003288231A AU 2003288231 A AU2003288231 A AU 2003288231A AU 2003288231 A1 AU2003288231 A1 AU 2003288231A1
Authority
AU
Australia
Prior art keywords
cyp46
hydroxylase
alzheimer
cholesterol
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003288231A
Other versions
AU2003288231A8 (en
Inventor
Stefan Golz
Martin Guldenagel
Gerhard Konig
Yan-Hong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of AU2003288231A8 publication Critical patent/AU2003288231A8/en
Publication of AU2003288231A1 publication Critical patent/AU2003288231A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/60Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003288231A 2002-12-13 2003-12-05 Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease Abandoned AU2003288231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02027692 2002-12-13
EP02027692.9 2002-12-13
PCT/EP2003/013760 WO2004055201A2 (en) 2002-12-13 2003-12-05 Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2003288231A8 AU2003288231A8 (en) 2004-07-09
AU2003288231A1 true AU2003288231A1 (en) 2004-07-09

Family

ID=32524000

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003288231A Abandoned AU2003288231A1 (en) 2002-12-13 2003-12-05 Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease

Country Status (2)

Country Link
AU (1) AU2003288231A1 (en)
WO (1) WO2004055201A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2582200T3 (en) * 2007-09-12 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of viral vectors carrying the CYP46A1 gene for the treatment of Alzheimer's disease
ES2566495T3 (en) 2010-10-15 2016-04-13 Inserm - Institut National De La Santé Et De La Recherche Médicale Expression vector for 24-hydrolase cholesterol in Huntington's disease therapy
WO2013036835A1 (en) 2011-09-08 2013-03-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JP6117191B2 (en) 2011-10-07 2017-04-19 武田薬品工業株式会社 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
RS67266B1 (en) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroactive steriods and methods of use thereof
RU2021111681A (en) * 2013-03-13 2021-05-11 Сейдж Терапьютикс, Инк. NEUROACTIVE STEROIDS, COMPOSITIONS AND THEIR APPLICATION
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
BR112018000129B1 (en) 2015-07-06 2024-01-09 Sage Therapeutics, Inc Oxysterol compounds, their uses and pharmaceutical composition
JP6882996B2 (en) 2015-07-06 2021-06-02 セージ セラピューティクス, インコーポレイテッド Oxysterols and how to use them
SMT202100476T1 (en) 2015-07-06 2021-09-14 Sage Therapeutics Inc Oxysterols and methods of use thereof
SI3436022T1 (en) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (en) 2016-07-07 2021-12-10 Sage Therapeutics Inc 11-substituted 24-hydroxysteroles for the treatment of NMDA-related conditions
MX392270B (en) 2016-09-30 2025-03-24 Sage Therapeutics Inc C7-SUBSTITUTED OXYSTEROLS AND METHODS OF USING THEM.
EP4105223B1 (en) 2016-10-18 2025-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN110267966B (en) 2016-10-18 2022-07-08 萨奇治疗股份有限公司 Oxysterols and methods of using the same
IL301525A (en) * 2020-09-21 2023-05-01 Asklepios Biopharmaceutical Inc Methods for treating neurological disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048492A1 (en) * 2001-11-09 2005-03-03 Andreas Papassotiropoulos Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determining cyp46 genotype

Also Published As

Publication number Publication date
AU2003288231A8 (en) 2004-07-09
WO2004055201A3 (en) 2004-08-19
WO2004055201A2 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
AU2003229937A1 (en) Alkynyl-substituted spirocyclic sulfamides for the treatment of alzheimer's disease
AU2003288231A1 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
SI2527315T1 (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
IL159320A0 (en) Compounds for the treatment of metabolic disorders
AU2002362774A1 (en) Cyclosporin analogs for the treatment of lung diseases
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AU2002312897A1 (en) Drugs for the treatment of the alzheimer disease
AU2001236592A1 (en) Methods for diagnosis of alzheimer's disease
AU7408301A (en) Novel target genes for diseases of the heart
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003303141A1 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2003298178A1 (en) Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
AU2003284898A1 (en) Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU2003266302A1 (en) Method for the diagnosis of alzheimer disease
AU2003277298A1 (en) Pharmaceutical compositions for treatment of parkinson's disease
AU2003216696A1 (en) Methods for the selection of compounds useful for the treatment of huntington's disease
AU2003260745A1 (en) Sulphonylamino derivatives for the treatment of alzheimer's disease
AU2002320537A1 (en) Diaminediols for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase